Loading…
← CockpitCompetitor Analysis › BBTX Bambusa Therapeutics, Inc.Open in the cockpit ↗

Bambusa Therapeutics, Inc.BBTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Mkt cap
$791M
US dollars, full cap
$/day
$6.13M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.1%
Hurdle
n/a
no reverse DCF
Close · USD$15.90
1D-2.8%
1W-7.3%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Bambusa Therapeutics does

Employees: 26

Bambusa Therapeutics at a glance

Size Bambusa Therapeutics (BBTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $791M, the 2377th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.90 on 18 Nov 2026.

Bambusa Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a$0$0
EBITDAn/a-$44.0M-$13.9M
Net incomen/a-$41.1M-$13.7M
Free cash flown/a-$39.8M-$4.63M
Capital expendituren/a$0$0
Total debtn/a$135M$14.0M

Quarterly statements and history in the cockpit →

Bambusa Therapeutics competitors and peer comparison

How Bambusa Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a

Questions

Which companies are Bambusa Therapeutics's closest peers?
The cockpit's peer set: Ironwood Pharmaceuticals (IRWD), Knight Therapeutics (GUD.TO), Oric Pharmaceuticals (ORIC), Sanofi India (SANOFI.NS), Jinghua Pharmaceutical (002349.SZ), Ardelyx (ARDX), Zhejiang Int'l (000411.SZ), Rigel Pharmaceuticals (RIGL).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.